Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Multiple Sclerosis

Free Subscription 16.06.2025 1 Ann Neurol 1 Brain 1 Can J Neurol Sci 2 J Neurol 1 J Neurol Neurosurg Psychiatry 4 J Neurol Sci 1 Mult Scler 2 Neurol Clin Pract 1 Proc Natl Acad Sci U S A 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. DISANTO G, Sacco R, Mallucci G, Zecca C, et al
   Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
   Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
   PubMed         Abstract available
   
   

   
   Brain

2. CUNNIFFE NG
   Extending the role of neurofilament light in multiple sclerosis beyond measuring irreversible neurodegeneration.
   Brain. 2025 Jun 9:awaf224. doi: 10.1093.
   PubMed        
   
   

   
   Can J Neurol Sci

3. FREEDMAN MS, Clift F, Devonshire V, Emond F, et al
   First-line use of higher-efficacy disease-modifying therapies in multiple sclerosis: Canadian consensus recommendations.
   Can J Neurol Sci. 2025 Jun 9:1-28. doi: 10.1017/cjn.2025.10342.
   PubMed        
   
   

   
   J Neurol

4. BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
   Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
   J Neurol. 2025;272:454.
   PubMed         Abstract available
   
   
5. ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
   Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
   J Neurol. 2025;272:446.
   PubMed         Abstract available
   
   

   
   J Neurol Neurosurg Psychiatry

6. ABDELHAK A, Bachhuber F, Ning K, Benkert P, et al
   Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
   J Neurol Neurosurg Psychiatry. 2025 Jun 12:jnnp-2025-335831.
   PubMed         Abstract available
   
   

   
   J Neurol Sci

7. KVARTSKHAVA T, Freudenstein D, Sarmiento N, Angstwurm K, et al
   Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis.
   J Neurol Sci. 2025;475:123577.
   PubMed         Abstract available
   
   
8. DEVOGELAERE J, Van Remoortel A, Van Laethem D, Faille LD, et al
   Impact of brain volume on coronavirus disease of 2019 severity and subsequent cognitive decline in patients with multiple sclerosis.
   J Neurol Sci. 2025;475:123552.
   PubMed         Abstract available
   
   
9. NOVARELLA F, Nicolella V, Fiorenza M, Falco F, et al
   Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis.
   J Neurol Sci. 2025;475:123562.
   PubMed         Abstract available
   
   
10. ABBADESSA G, Schiavetti I, Bollo L, Cellerino M, et al
    Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study.
    J Neurol Sci. 2025;474:123533.
    PubMed         Abstract available
    
    

    
    Mult Scler

11. STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al
    Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
    Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757.
    PubMed         Abstract available
    
    

    
    Neurol Clin Pract

12. BALSHI A, Leuenberger G, Dempsey J, Manning N, et al
    Erratum: Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study.
    Neurol Clin Pract. 2025;15:e200505.
    PubMed         Abstract available
    
    
13. SALTER A, Lancia S, Sharma M, Cutter GR, et al
    Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis.
    Neurol Clin Pract. 2025;15:e200493.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

14. 
    Editorial Expression of Concern for Poon et al., Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.
    Proc Natl Acad Sci U S A. 2025;122:e2512750122.
    PubMed        
    
    

    
    Rev Neurol (Paris)

15. LERAY E, Drezen E, Casey R, Vukusic S, et al
    Data linkage between the French multiple sclerosis cohort (OFSEP) and the French national health insurance database (SNDS).
    Rev Neurol (Paris). 2025 Jun 5:S0035-3787(25)00537.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.